1/16
08:30 am
pali
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Medium
Report
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
1/9
07:00 am
pali
Palisade Bio (NASDAQ:PALI) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
Low
Report
Palisade Bio (NASDAQ:PALI) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
1/7
08:27 am
pali
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 [Yahoo! Finance]
Low
Report
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 [Yahoo! Finance]
1/7
08:15 am
pali
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
Medium
Report
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
1/3
01:08 am
pali
1/1
05:45 am
pali
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.
Medium
Report
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.
12/30
12:15 pm
pali
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 [Yahoo! Finance]
Low
Report
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 [Yahoo! Finance]
12/30
08:35 am
pali
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
Medium
Report
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
12/30
07:09 am
pali
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
12/29
06:02 am
pali
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
12/25
10:47 am
pali
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results [Yahoo! Finance]
Low
Report
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results [Yahoo! Finance]
12/22
08:48 pm
pali
Palisade Bio: Gut Prodrug For IBD With Catalysts [Seeking Alpha]
Low
Report
Palisade Bio: Gut Prodrug For IBD With Catalysts [Seeking Alpha]
12/2
08:45 am
pali
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Medium
Report
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
11/25
08:45 am
pali
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
11/21
07:04 pm
pali
Individual investors are Palisade Bio, Inc.'s (NASDAQ:PALI) biggest owners and were rewarded after market cap rose by US$70m last week [Yahoo! Finance]
Medium
Report
Individual investors are Palisade Bio, Inc.'s (NASDAQ:PALI) biggest owners and were rewarded after market cap rose by US$70m last week [Yahoo! Finance]
11/11
05:02 pm
pali
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/28
08:45 am
pali
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
High
Report
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations